Dashboard
Manage Tickers

NVS NOVARTIS AG

NYSE novartis.com


$ 122.16 $ -1.01 (-0.82 %)    

Wednesday, 29-Oct-2025 15:08:51 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 633.71 $ -1.87 (-0.29 %)
DIA $ 476.49 $ -2.11 (-0.44 %)
SPY $ 686.09 $ -2.69 (-0.39 %)
TLT $ 91.23 $ -0.65 (-0.71 %)
GLD $ 364.69 $ -4.96 (-1.34 %)
$ 123.43
$ 123.18
$ 121.91 x 400
$ 122.18 x 15
$ 121.65 - $ 123.93
$ 92.72 - $ 133.55
4,631,015
na
243.79B
$ 0.48
$ 20.42
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

novartis-ianalumab-first-drug-to-reduce-disease-activity-and-patient-burden-in-sjgrens-disease-phase-iii-trials
Novartis Ianalumab First Drug To Reduce Di...
10/29/2025 14:40:37

https://www.globenewswire.com/news-release/2025/10/29/3176619/0/en/Novartis-ianalumab-first-drug-to-reduce-disease-activity-and...

is-the-market-bullish-or-bearish-on-novartis-ag
Is the Market Bullish or Bearish on Novart...
10/29/2025 14:00:51

earnings-scheduled-for-october-28-2025
Earnings Scheduled For October 28, 2025
10/28/2025 11:11:34

novartis-maintains-outlook-even-as-generics-bite-into-profits
Novartis Maintains Outlook Even As Generic...
10/28/2025 10:58:47

Novartis Q3 sales rose 8% to $13.91 billion, missing estimates, as Kisqali and Kesimpta drove growth while U.S. generics weighe...

merger-monday-makes-comeback-as-us-ma-tops-80-billion-in-24-hours
'Merger Monday' Makes Comeback As US M&A T...
10/28/2025 09:44:49

U.S. companies have struck more than $80 billion worth of deals in the past 24 hours, in the latest sign that mergers and acqui...

novartis-reaffirmed-its-full-year-2025-guidance-maintaining-expectations-for-high-single-digit-sales-growth-and-low-teens-core-operating-income-growth
Novartis Reaffirmed Its Full-Year 2025 Gui...
10/28/2025 07:03:00

novartis-q3-adj-eps-225-inline-sales-13909b-miss-14105b-estimate
Novartis Q3 Adj. EPS $2.25, Inline, Sales ...
10/28/2025 06:56:36

Novartis (NYSE:NVS) reported quarterly earnings of $2.25 per share which met the analyst consensus estimate. This is a 9.22 per...

avidity-biosciences-soars-after-72-per-share-novartis-takeover
Avidity Biosciences Soars After $72 Per Sh...
10/27/2025 18:52:41

Avidity Biosciences (RNA) to be acquired by Novartis in a $12 billion cash deal. H.C. Wainwright downgrades to Neutral.

what-to-expect-from-novartiss-earnings
What to Expect from Novartis's Earnings
10/27/2025 14:02:47

avidity-shareholders-win-big-as-novartis-moves-fast-on-12-billion-deal
Avidity Shareholders Win Big As Novartis M...
10/27/2025 10:11:40

Avidity Biosciences (NASDAQ: RNA) shares soar as Novartis (NYSE: NVS) agrees to acquire them for $12 billion in cash.

stock-market-today-nasdaq-dow-jones-sp-500-futures-climb-ahead-of-busy-week-on-wall-streetnovartis-nucor-waste-management-in-focus-updated
Stock Market Today: Nasdaq, Dow Jones, S&P...
10/27/2025 10:02:00

Editor’s note: The future prices of benchmark tracking ETFs, and the headline were updated in the story.

why-avidity-biosciences-shares-are-trading-higher-by-around-42-here-are-20-stocks-moving-premarket
Why Avidity Biosciences Shares Are Trading...
10/27/2025 08:53:30

Core News & Articles
Reported Sunday, Novartis Agrees To Acquir...
10/27/2025 06:36:33

Transaction strengthens neuroscience franchise for Novartis with three late-stage programs that address genetic neuromuscular d...

Core News & Articles
Novartis On Sunday Announced The Acquisiti...
10/26/2025 19:24:06

Novartis today announced that it has entered into an agreement to acquire Avidity Biosciences, Inc. (NASDAQ:RNA), a San Diego-b...

jim-cramer-time-to-pull-the-trigger-on-kratos-a-terrific-stock
Jim Cramer: Time To 'Pull The Trigger' On ...
10/24/2025 12:21:28

Kratos secured a $68.3 million deal and a contract through the Defense Department's Industrial Base Analysis and Sustainmen...

novartis-cosentyx-trial-shows-efficacy-in-patients-with-stiff-joints-and-muscle-pain
Novartis Cosentyx Trial Shows Efficacy In ...
10/22/2025 18:35:12

Novartis' Cosentyx Phase 3 REPLENISH trial for polymyalgia rheumatica met primary and secondary endpoints, showing signific...

novartis-cancer-drug-shows-sustained-benefit-in-five-year-breast-cancer-trial
Novartis Cancer Drug Shows Sustained Benef...
10/17/2025 18:02:58

Novartis' five-year NATALEE trial shows Kisqali plus endocrine therapy reduces recurrence risk and improves breast cancer s...

novartis-announces-5-year-results-from-phase-iii-natalee-trial-of-kisqali
Novartis Announces 5-Year Results From Pha...
10/17/2025 12:33:26

After 5 years, Kisqali® plus endocrine therapy consistently shows significant and clinically meaningful benefit in invasive dis...

small-cap-biotech-climb-bios-lead-drug-candidate-has-larger-long-term-opportunity
Small-Cap Biotech Climb Bio's Lead Drug Ca...
10/16/2025 17:40:28

William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therap...

novartis-strengthens-kidney-disease-pipeline-with-promising-data
Novartis Strengthens Kidney Disease Pipeli...
10/16/2025 14:50:29

Novartis' Fabhalta showed significant efficacy and safety in a Phase 3 IgA nephropathy study, supporting regulatory filings...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION